L3VLUP
ProSign in

RCUS · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

RCUSVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • RCUS
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterRCUSVRTX
Q3 20204 holders, $12m31 holders, $21.9bn
Q4 20202 holders, $14m30 holders, $18.4bn
Q1 20212 holders, $48m31 holders, $15.4bn
Q2 20212 holders, $48m30 holders, $12.7bn
Q3 20211 holders, $59m35 holders, $10.1bn
Q4 20213 holders, $81m28 holders, $12.4bn
Q1 20221 holders, $8.3m23 holders, $16.1bn
Q2 20221 holders, $3.8m25 holders, $18.1bn
Q3 20221 holders, $1.5m22 holders, $18.4bn
Q4 20222 holders, $26m28 holders, $18.4bn
Q1 20235 holders, $28m26 holders, $21.4bn
Q2 20236 holders, $69m27 holders, $24.7bn
Q3 20232 holders, $23m33 holders, $24.3bn
Q4 20234 holders, $27m32 holders, $28.6bn
Q1 20245 holders, $97m31 holders, $29.8bn
Q2 20244 holders, $95m29 holders, $33.4bn
Q3 20245 holders, $103m27 holders, $33.5bn
Q4 20244 holders, $85m26 holders, $28.5bn
Q1 20254 holders, $64m21 holders, $35.4bn
Q2 20253 holders, $84m21 holders, $32.3bn
Q3 20254 holders, $117m22 holders, $25.9bn
Q4 20256 holders, $265m26 holders, $31.8bn
Q1 20265 holders, $310m25 holders, $31.8bn
Q2 20265 holders, $346m26 holders, $34.6bn
RCUS

Arcus Biosciences Inc

Holders
5
Reported value
$346m
Buyers
13
Sellers
15

Breadth -2 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$34.6bn
Buyers
21
Sellers
17

Breadth +4 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2026

Among the 28 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only RCUS (2)

PDT Partners LLC, Winton Group Ltd

Only VRTX (23)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Baillie Gifford & Co, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Fidelity (FMR LLC), Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Two Sigma Investments LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →